Showing 4101-4110 of 5911 results for "".
- ViaLase Completes Enrollment for the VIA-002 Trial of the ViaLase Laser to Treat Primary Open Angle Glaucomahttps://modernod.com/news/vialase-completes-enrollment-for-the-via-002-trial-of-the-vialase-laser-to-treat-primary-open-angle-glaucoma/2481921/ViaLase announced it has completed enrollment of VIA-002, the company's pivotal trial of the ViaLase Laser to treat adult patients with primary open angle glaucoma (POAG). The ViaLase Laser combines the precision of femtosecond laser technology and the accuracy of micron-level image
- FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)https://modernod.com/news/fda-approves-genentechs-vabysmo-for-the-treatment-of-retinal-vein-occlusion-rvo/2481917/The FDA has approved Genentech's Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). The approval for RVO marks the third indication for Vabysmo, along with wet age-related macular degeneration (AMD) and diabetic macular edem
- Vision Innovation Partners Names Chris Moore as CEOhttps://modernod.com/news/vision-innovation-partners-names-chris-moore-as-ceo/2481914/Vision Innovation Partners (VIP), a Mid-Atlantic eye care platform with nearly 70 locations, announced the promotion of existing board member and current President, Chris Moore, to Chief Executive Officer. Former CEO and founder Mike Dunn is now serving as Executive Vice President of Business Dev
- Bausch + Lomb Introduces New Surgical Planning Software for Eyetelligence Platformhttps://modernod.com/news/bausch-lomb-introduces-new-surgical-planning-software-for-eyetelligence-platform/2481907/Bausch + Lomb introduced new surgical planning software for the Eyetelligence platform designed to streamline surgical planning, information flow, and enable elect
- Lighthouse Guild Presents 2023 Awardshttps://modernod.com/news/lighthouse-guild-presents-2023-awards/2481905/Lighthouse Guild hosted its 2023 lecture and awards ceremony at its headquarters in New York on October 19. The awards recognize outstanding accomplishments in vision science, technological innovation, and advocacy. Wiley A. Chambers, MD, was awarded
- Stuart Therapeutics Enters License Agreement with Glaukos for Preclinical Glaucoma Drug Candidatehttps://modernod.com/news/stuart-therapeutics-enters-license-agreement-with-glaukos-for-preclinical-glaucoma-drug-candidate/2481904/Stuart Therapeutics has entered into a license agreement with Glaukos under which it has granted Glaukos exclusive worldwide rights to develop and commercialize Stuart's proprietary ST-113 drug candidate for neuroprotection in glaucoma. ST-113 is a pat
- The Lancet Publishes 24-Month Results from Phase 3 Studies of Syfovre for GAhttps://modernod.com/news/the-lancet-publishes-24-month-results-from-phase-3-studies-of-syfovre-for-geographic-atrophy/2481901/Apellis Pharmaceuticals announced that The Lancet has published 24-month results from the phase 3 OAKS and DERBY studies evaluating Syfovre (pegcetacoplan injection)
- Bausch + Lomb Launches enVista Aspire Monofocal and Toric IOLshttps://modernod.com/news/bausch-lomb-launches-envista-aspire-monofocal-and-toric-iols/2481897/Bausch + Lomb announced the launch of the enVista Aspire monofocal and toric IOLs in the United States. The enVista Aspire IOLs featured B+L's Intermediate Optimized (IO) optics, which are designed for a broader depth of focus, with the benefits of the enVista platform to address patient
- FDA Finds 'Substantive' Issues in Aldeyra’s NDA for Reproxalap for Dry Eye Diseasehttps://modernod.com/news/fda-finds-substantive-issues-in-aldeyras-reproxalap-drug-candidate-for-dry-eye-disease/2481895/Aldeyra Therapeutics was dealt a major setback this week as the FDA identified "substantive review issues" in the company’s new drug application for dry-eye disease treatment candidate reproxalap. In a US securities
- Optos Unveils New Retinal Imaging Technology at Euretinahttps://modernod.com/news/optos-unveils-new-retinal-imaging-technology-at-euretina/2481893/Optos announced advances to its ultra-widefield multimodal retinal imaging at its satellite symposia at the Euretina congress in Amsterdam. Optos’ devices capture ultra-widefield (UWFTM) high-resolution optomap images of 200 degress of the retina in a sing